Universal Beteiligungs und Servicegesellschaft mbH Buys New Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 114,587 shares of the company's stock, valued at approximately $4,610,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of Kymera Therapeutics at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $55,000. Woodline Partners LP increased its position in shares of Kymera Therapeutics by 2.3% during the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company's stock worth $21,621,000 after acquiring an additional 12,334 shares during the period. Vident Advisory LLC purchased a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $236,000. State of Wyoming bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $45,000. Finally, ProShare Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 33.3% in the fourth quarter. ProShare Advisors LLC now owns 16,293 shares of the company's stock valued at $655,000 after purchasing an additional 4,071 shares during the period.

Kymera Therapeutics Stock Up 1.0%

Shares of NASDAQ KYMR traded up $0.45 during midday trading on Tuesday, hitting $43.58. The company had a trading volume of 3,523,238 shares, compared to its average volume of 603,189. The business has a 50-day simple moving average of $28.84 and a two-hundred day simple moving average of $35.59. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -18.62 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics's quarterly revenue was up 114.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.69) earnings per share. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

KYMR has been the topic of a number of recent research reports. B. Riley raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $38.00 to $60.00 in a research report on Tuesday. UBS Group lowered their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. HC Wainwright lifted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Guggenheim reissued a "buy" rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research note on Monday, May 12th. Finally, Stifel Nicolaus began coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a "buy" rating and a $55.00 target price on the stock. Two analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $59.35.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.